A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV—short for respiratory syncytial virus—vaccine. VISION Network researchers report that across the board these vaccines were highly effective in older adults, even those with immunocompromising conditions, during the 2023–24 respiratory disease season, the first season after RSV vaccine approval in the U.S.
Study finds RSV vaccine highly effective in protecting older adults against severe disease, hospitalization and death
